Compare DAO & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAO | NVAX |
|---|---|---|
| Founded | 2006 | 1987 |
| Country | China | United States |
| Employees | 3595 | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2019 | 1996 |
| Metric | DAO | NVAX |
|---|---|---|
| Price | $12.02 | $8.91 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.33 |
| AVG Volume (30 Days) | 48.3K | ★ 4.9M |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | $12.24 | N/A |
| Revenue Next Year | $14.60 | N/A |
| P/E Ratio | $72.35 | ★ N/A |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $8.00 | $6.20 |
| 52 Week High | $13.04 | $11.85 |
| Indicator | DAO | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 58.65 | 51.25 |
| Support Level | $8.96 | $7.75 |
| Resistance Level | $13.00 | $9.02 |
| Average True Range (ATR) | 1.05 | 0.67 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 59.85 | 41.12 |
Youdao Inc develops and markets software applications. It engages in developing technologies to provide learning content, applications, and solutions. The firm operates in three segments: Learning services, Smart devices, and Online marketing services. The majority of its revenue comes from the Learning services segment, which generates revenues from online courses, mainly including Youdao Premium Courses, NetEase Cloud Classroom, and China University MOOC. The learning products segment includes sales of smart devices such as the Youdao Dictionary Pen and the Youdao Pocket Translator. Geographically, all of its revenue is generated from the People's Republic of China.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.